Integrated Biosciences Extends Optogenetic Screening Platform to Age-Related Disease Targets
The modular, AI-driven system has moved beyond antiviral validation to in vivo discovery of precise stress-response modulators for hard-to-drug aging pathways.
Overview
- The optogenetic platform combines programmable light-responsive domains with automated high-throughput chemistry to achieve millisecond temporal and micron-scale spatial control in screening assays.
- Application to the integrated stress response yielded ISR-potentiating compounds that sensitize stressed cells to apoptosis without detectable off-target toxicity.
- Lead molecules demonstrated broad-spectrum antiviral activity in vitro and significantly reduced ocular herpesvirus disease and viral titers in mouse models.
- Integrated Biosciences is now validating the system in additional in vivo models of age-related pathways that have eluded conventional drug screening.
- A graph neural network–driven AI engine analyzes high-fidelity screening data to navigate complex chemical space and accelerate precise hit discovery.